MR Spectroscopy as a Diagnostic and Outcome Measure in Pain and SCI (MRS)
The goal of this study is to compare the changes that occur in sensation and chemical properties of the brain following SCI between individuals that experience chronic pain and those that do not, and between those with SCI and the able-bodied.
Spinal Cord Injury
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||MR Spectroscopy (MRS) as a Diagnostic and Outcome Measure in Pain and SCI|
- Using MR Spectroscopy to measure the concentration of N-acetyl aspartate, glutamate/glutamine, and myo-inositol in the areas of the brain thought to process pain. [ Time Frame: Two measures at intervals of 2 to 4 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||October 2007|
|Study Completion Date:||September 2010|
|Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
Spinal cord injured with chronic central neuropathic pain.
Spinal cord injured without chronic central neuropathic pain.
Able-bodied without history of chronic pain of any type
Traumatically Brain Injured with a history of pain that onset after their TBI
This study investigates the differences in certain neurochemicals present in areas of the brain linked to pain processing in people with SCI and neuropathic pain, in people with SCI but no pain, and in able-bodied persons. We will also investigate the relationship between these concentrations of neurochemicals and different aspects of chronic neuropathic pain, including the intensity of pain, quality of life issues, sensitivity changes in areas of the body that are both painful and non-painful, and neurological status.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00561782
|United States, Florida|
|VA Medical Center, Miami|
|Miami, Florida, United States, 33125|
|Principal Investigator:||Eva G. Widerstrom-Noga, DDS PhD||VA Medical Center, Miami|